It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GIKLY’s FA Score shows that 1 FA rating(s) are green whileGLAXF’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GIKLY’s TA Score shows that 2 TA indicator(s) are bullish while GLAXF’s TA Score has 3 bullish TA indicator(s).
GIKLY (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while GLAXF (@Pharmaceuticals: Major) price change was -4.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.43%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +13.43%.
GIKLY is expected to report earnings on Nov 06, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
GIKLY | GLAXF | GIKLY / GLAXF | |
Capitalization | 8.79B | 104B | 8% |
EBITDA | 726M | 10B | 7% |
Gain YTD | 59.255 | 7.935 | 747% |
P/E Ratio | 75.19 | 17.36 | 433% |
Revenue | 6.46B | 36.5B | 18% |
Total Cash | 557M | 14B | 4% |
Total Debt | 10.9B | 33.3B | 33% |
GIKLY | GLAXF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 82 | 40 | |
PRICE GROWTH RATING 1..100 | 37 | 60 | |
P/E GROWTH RATING 1..100 | 76 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GLAXF's Valuation (8) in the null industry is in the same range as GIKLY (21). This means that GLAXF’s stock grew similarly to GIKLY’s over the last 12 months.
GLAXF's Profit vs Risk Rating (100) in the null industry is in the same range as GIKLY (100). This means that GLAXF’s stock grew similarly to GIKLY’s over the last 12 months.
GLAXF's SMR Rating (40) in the null industry is somewhat better than the same rating for GIKLY (82). This means that GLAXF’s stock grew somewhat faster than GIKLY’s over the last 12 months.
GIKLY's Price Growth Rating (37) in the null industry is in the same range as GLAXF (60). This means that GIKLY’s stock grew similarly to GLAXF’s over the last 12 months.
GLAXF's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for GIKLY (76). This means that GLAXF’s stock grew somewhat faster than GIKLY’s over the last 12 months.
GIKLY | GLAXF | |
---|---|---|
RSI ODDS (%) | N/A | 1 day ago62% |
Stochastic ODDS (%) | 1 day ago67% | 1 day ago60% |
Momentum ODDS (%) | 1 day ago64% | 1 day ago49% |
MACD ODDS (%) | 1 day ago52% | 1 day ago54% |
TrendWeek ODDS (%) | 1 day ago56% | 1 day ago56% |
TrendMonth ODDS (%) | 1 day ago58% | 1 day ago57% |
Advances ODDS (%) | N/A | 12 days ago64% |
Declines ODDS (%) | N/A | 3 days ago51% |
BollingerBands ODDS (%) | 1 day ago65% | 1 day ago67% |
Aroon ODDS (%) | 1 day ago68% | 1 day ago45% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
PPT | 3.69 | 0.01 | +0.27% |
Putnam Premier Income Trust | |||
EFFI | 23.09 | N/A | N/A |
Harbor Osmosis International Resource Efficient ETF | |||
MYLD | 23.68 | N/A | -0.02% |
Cambria Micro and Smcp Shld Yld ETF | |||
SIXS | 47.54 | -0.31 | -0.64% |
ETC 6 Meridian Small Cap Equity ETF | |||
FTLS | 66.30 | -0.58 | -0.87% |
First Trust Long/Short Equity ETF |
A.I.dvisor indicates that over the last year, GIKLY has been closely correlated with GRFS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GIKLY jumps, then GRFS could also see price increases.
Ticker / NAME | Correlation To GIKLY | 1D Price Change % | ||
---|---|---|---|---|
GIKLY | 100% | N/A | ||
GRFS - GIKLY | 68% Closely correlated | +0.19% | ||
GIFOF - GIKLY | 27% Poorly correlated | N/A | ||
GIFLF - GIKLY | 25% Poorly correlated | N/A | ||
ORINY - GIKLY | 9% Poorly correlated | -12.25% | ||
OPHLY - GIKLY | 8% Poorly correlated | -0.45% | ||
More |
A.I.dvisor indicates that over the last year, GLAXF has been loosely correlated with GSK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAXF jumps, then GSK could also see price increases.
Ticker / NAME | Correlation To GLAXF | 1D Price Change % | ||
---|---|---|---|---|
GLAXF | 100% | N/A | ||
GSK - GLAXF | 37% Loosely correlated | +2.26% | ||
OPHLY - GLAXF | 9% Poorly correlated | -0.45% | ||
HAWPF - GLAXF | 8% Poorly correlated | N/A | ||
ORINY - GLAXF | 6% Poorly correlated | -12.25% | ||
GIKLY - GLAXF | 5% Poorly correlated | N/A | ||
More |